
Entasis Therapeutics Holdings ETTX
Quartalsbericht 2022-Q1
hinzugefügt 23.12.2023
Entasis Therapeutics Holdings Langfristiger Schuldenstrom 2011-2026 | ETTX
Langfristiger Schuldenstrom Jährlich Entasis Therapeutics Holdings
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 704 K | 617 K | 506 K | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 704 K | 506 K | 609 K |
Langfristiger Schuldenstrom anderer Aktien in der Pharmaeinzelhändler
| Name | Langfristiger Schuldenstrom | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
3.63 M | - | 2.43 % | $ 254 M | ||
|
Acorda Therapeutics
ACOR
|
1.59 M | - | -24.86 % | $ 820 K | ||
|
Adverum Biotechnologies
ADVM
|
5.67 M | - | - | $ 86.2 M | ||
|
ACADIA Pharmaceuticals
ACAD
|
9.96 M | $ 22.56 | 2.13 % | $ 3.74 B | ||
|
AlloVir
ALVR
|
316 K | - | 4.14 % | $ 49.1 M | ||
|
Applied Molecular Transport
AMTI
|
4.64 M | - | - | $ 10.1 M | ||
|
Applied Therapeutics
APLT
|
429 K | - | - | $ 8.42 M | ||
|
Akebia Therapeutics
AKBA
|
3.55 M | $ 1.43 | 3.62 % | $ 368 M | ||
|
argenx SE
ARGX
|
10.8 M | $ 785.07 | 2.57 % | $ 25 B | ||
|
I-Mab
IMAB
|
8.06 M | - | - | $ 866 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
45.5 M | $ 327.25 | 2.42 % | $ 42.9 B | ||
|
Aytu BioScience
AYTU
|
137 K | $ 2.66 | 3.5 % | $ 16.7 M | ||
|
AVROBIO
AVRO
|
878 K | - | 1083.1 % | $ 745 M | ||
|
Ayala Pharmaceuticals
AYLA
|
419 K | - | - | $ 7.46 M | ||
|
AstraZeneca PLC
AZN
|
382 M | - | - | $ 96.9 B | ||
|
BeiGene, Ltd.
BGNE
|
20.7 M | - | 0.49 % | $ 251 B | ||
|
Alterity Therapeutics Limited
ATHE
|
57.6 K | $ 3.9 | 3.7 % | $ 9.38 B | ||
|
CymaBay Therapeutics
CBAY
|
7 K | - | - | $ 3.45 B | ||
|
Advaxis
ADXS
|
166 K | - | -9.65 % | $ 45.9 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
7.93 M | $ 20.4 | -0.87 % | $ 954 M | ||
|
Aquestive Therapeutics
AQST
|
631 K | $ 4.18 | 1.21 % | $ 447 M | ||
|
Avid Bioservices
CDMO
|
1.35 M | - | - | $ 789 M | ||
|
Cidara Therapeutics
CDTX
|
1.38 M | - | - | $ 1.41 B | ||
|
Arcutis Biotherapeutics
ARQT
|
294 K | $ 24.61 | 5.76 % | $ 3.13 B | ||
|
Cabaletta Bio
CABA
|
3.46 M | $ 3.09 | 0.65 % | $ 310 M | ||
|
Aeterna Zentaris
AEZS
|
271 K | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
181 K | - | -10.17 % | $ 12.2 K | ||
|
Concert Pharmaceuticals
CNCE
|
1.16 M | - | - | $ 401 M | ||
|
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
1.27 M | - | - | $ 26.5 M | ||
|
Autolus Therapeutics plc
AUTL
|
4.56 M | $ 1.49 | 9.56 % | $ 397 M | ||
|
CTI BioPharma Corp.
CTIC
|
781 K | - | - | $ 1.2 B | ||
|
AIkido Pharma
AIKI
|
554 K | - | 1.93 % | $ 17.4 M | ||
|
Aptose Biosciences
APTO
|
193 K | - | -45.71 % | $ 1.2 M | ||
|
Deciphera Pharmaceuticals
DCPH
|
3.5 M | - | - | $ 2.18 B | ||
|
Dynavax Technologies Corporation
DVAX
|
4.18 M | - | - | $ 2.02 B | ||
|
Forte Biosciences
FBRX
|
416 K | $ 26.27 | 0.38 % | $ 340 M | ||
|
CureVac N.V.
CVAC
|
3.47 M | - | - | $ 867 M | ||
|
Akouos
AKUS
|
671 K | - | 0.23 % | $ 488 M |